Occurrence and determinants of trimethoprim/sulfamethoxazole use in pregnancy

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 11, 2007, Pages 1310-1316

  Yang, Tubao ^a,b,c   Walker, Mark C ^b,c   Krewski, Daniel ^b   Yang, Qiuying ^b,c   Garner, Peter ^b   Fraser, William ^d   Olatunbosun, Olufemi ^e   Nimrod, Carl ^b   Wen, Shi Wu ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Chronic diseases; Pregnancy; Saskatchewan; Social assistance; Teenage; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; SOCIOECONOMICS;

ADULT; ANTI-INFECTIVE AGENTS, URINARY; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HEALTH STATUS; HUMANS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTERS; RETROSPECTIVE STUDIES; SASKATCHEWAN; SOCIOECONOMIC FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 35648953411     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701660054     Document Type: Article

References (27)

1. Sivojelezova A, Einarson A, Shuhaiber S, Koren G; Motherisk Team. Trimethoprim-sulfonamide combination therapy in early pregnancy. Can Fam Phys. 2003;49:1085-6.
2. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother. 2000;46:49-52.
3. Huang E, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med. 2002;162:41-7.
4. Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can. 2004;26:475-80.
5. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608-14.
6. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153:961-8.
7. Czeisel A, Rockenbaer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population-based case control study. Reprod Toxicol. 2001;15:637-46.
8. Meijer WM, Walle HEK, Kerstjens-Frederikse WS, Jong-van den Berg LTW. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol. 2005;20:203-7.
9. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf. 2006;15:327-37.
10. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398-407.
11. Riley EH, Fuentes-Afflick E, Jackson RA, Escobar GJ, Brawarsky P, Schreiber M, et al. Correlates of prescription drug use during pregnancy. J Womens. Health. 2005;14:401-9.
12. Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol. 1987;157:148-56.
13. Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol. 1991;165:33-40.
14. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol. 1993;46:581-9.
15. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113:559-68.
16. Garriguet D. Medication use among pregnant women. Health Rep. 2006;17:9-18.
17. Lee E, Maneno MK, Smith L, Weiss SR, Zuckerman IH, Wutoh AK, et al. National patterns of medication use during pregnancy. Pharmcoepidemiol Drug Saf. 2006;15:537-45.
18. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194:961-6.
19. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
20. Masters PA, O'Bryan TA, Zurlo J, Miller D, Joshi N. Trimethoprim- sulfamethoxazole revisited. Arch Intern Med. 2003;163:402-10.
21. Banhidy F, Acs N, Puho EH, Czeizel AE. Maternal urinary tract infection and related drug treatments during pregnancy and risk of congenital abnormalities in the offspring. BJOG. 2006;113:1465-71.
22. Jolly MC, Sebire N, Harris J, Robinson S, Regan L. Obstetric risks of pregnancy in women less than 18 years old. Obstet Gynecol. 2000;96:962-6.
23. Al-Haddad AM. Urinary tract infection among pregnant women in Al-Mukalla district, Yemen. East Med Health J. 2005;11:505-10.
24. Rothman KJ. Modern epidemiology, second edition. Boston, MA: Little, Brown and Company; 1998.
25. Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during pregnancy: its association with maternal morbidity and perinatal outcome. Am J Public Health. 1994;84:405-10.
26. Hernandez-Diaz S. Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiol Drug Saf. 2006;15:613-7.
27. Williams JI, Young W. A summary of the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor CD, editors. Patterns of health care in Ontario. The ICES practice atlas, second edition. Ottawa: Canadian Medical Association; 1996.